PA8472901A1 - Formulaciones farmaceuticas - Google Patents

Formulaciones farmaceuticas

Info

Publication number
PA8472901A1
PA8472901A1 PA19998472901A PA8472901A PA8472901A1 PA 8472901 A1 PA8472901 A1 PA 8472901A1 PA 19998472901 A PA19998472901 A PA 19998472901A PA 8472901 A PA8472901 A PA 8472901A PA 8472901 A1 PA8472901 A1 PA 8472901A1
Authority
PA
Panama
Prior art keywords
pharmaceutical formulations
sildenafil
dosage forms
free base
oral dosage
Prior art date
Application number
PA19998472901A
Other languages
English (en)
Inventor
Cristi Bell-Huff
Thomas Francis Dolan
Angela Carol Gatlin Hausberger
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PA8472901A1 publication Critical patent/PA8472901A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Silicon Polymers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

ESTA INVENCION SE REFIERE A NUEVAS FORMULACIONES FARMACEUTICAS DEL COMPUESTO SILDENAFILO Y EN PARTICULAR A FORMAS DE DOSIFICACION ORAL DE DESINTEGRACION RAPIDA QUE CONTIENEN SILDENAFILO EN FORMA DE SU BASE LIBRE.
PA19998472901A 1998-05-15 1999-05-14 Formulaciones farmaceuticas PA8472901A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8564698P 1998-05-15 1998-05-15

Publications (1)

Publication Number Publication Date
PA8472901A1 true PA8472901A1 (es) 2000-09-29

Family

ID=22193027

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19998472901A PA8472901A1 (es) 1998-05-15 1999-05-14 Formulaciones farmaceuticas

Country Status (32)

Country Link
US (1) US20020002172A1 (es)
EP (1) EP0960621A3 (es)
JP (1) JPH11349483A (es)
KR (1) KR19990088249A (es)
CN (1) CN1251758A (es)
AP (1) AP9901534A0 (es)
AR (1) AR016481A1 (es)
AU (1) AU753478B2 (es)
BG (1) BG103396A (es)
BR (1) BR9902086A (es)
CA (1) CA2272042A1 (es)
CO (1) CO5060503A1 (es)
DZ (1) DZ2786A1 (es)
EA (1) EA002830B1 (es)
GT (1) GT199900061A (es)
HN (1) HN1999000066A (es)
HR (1) HRP990144A2 (es)
HU (1) HUP9901606A2 (es)
ID (1) ID23299A (es)
IS (1) IS5046A (es)
MA (1) MA26629A1 (es)
NO (1) NO992339L (es)
NZ (1) NZ335772A (es)
OA (1) OA11040A (es)
PA (1) PA8472901A1 (es)
PE (1) PE20000546A1 (es)
PL (1) PL333118A1 (es)
SG (1) SG79255A1 (es)
SK (1) SK61599A3 (es)
TR (1) TR199901077A3 (es)
YU (1) YU21999A (es)
ZA (1) ZA993338B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000020033A1 (fr) * 1998-10-05 2000-04-13 Eisai Co., Ltd. Comprimes se delitant immediatement dans la cavite buccale
WO2000053148A2 (en) * 1999-03-08 2000-09-14 Merck & Co., Inc. Methods and compositions for treating erectile dysfunction
WO2000054777A1 (en) * 1999-03-16 2000-09-21 Pentech Pharmaceuticals, Inc. Controlled release of sildenafil delivered by sublingual or buccal administration
WO2000057857A1 (en) * 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
KR100344198B1 (ko) * 1999-10-08 2002-07-19 일양약품주식회사 실데나필 시트레이트의 속효제형
WO2002020058A1 (fr) 2000-09-06 2002-03-14 Tanabe Seiyaku Co., Ltd. Preparations administrees par voie orale
US6733781B2 (en) 2000-12-06 2004-05-11 Wyeth Fast dissolving tablet
IN192750B (es) * 2000-12-15 2004-05-15 Ranbaxy Lab Ltd
US6544552B2 (en) * 2001-01-11 2003-04-08 Particle And Coating Technologies, Inc. Method of producing porous tablets with improved dissolution properties
EP1226818A1 (en) * 2001-01-26 2002-07-31 Pfizer Products Inc. Pharmaceutical dosage forms with enhanced cohesive and compressibility properties
DK1392314T3 (da) * 2001-05-09 2007-03-12 Bayer Healthcare Ag Hidtil ukendt anvendelse af 2-[2-ethoxy-5-(4-methyl-piperazin-1-sulfonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]-triazin-4-on
LV12978B (en) * 2001-09-07 2003-05-20 Ivars Kalvins Pharmaceutical composition
CN1284532C (zh) * 2001-09-28 2006-11-15 株式会社三和化学研究所 有核型速溶崩解性成型品
US7118765B2 (en) 2001-12-17 2006-10-10 Spi Pharma, Inc. Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
SE0202365D0 (sv) * 2002-08-05 2002-08-05 Pharmacia Ab New formulation and use thereof
US7638138B2 (en) * 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
CN1758930B (zh) 2003-03-27 2010-06-09 株式会社新日本科学 鼻腔用粉末药剂喷药装置
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
US7670624B2 (en) 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
EP1785145A4 (en) * 2004-08-10 2008-08-13 Translational Res Ltd TRANSNASAL COMPOSITION WITH IMMEDIATE EFFECT AND HIGH RESORBIBILITY
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
US20070031349A1 (en) * 2005-06-23 2007-02-08 David Monteith Rapidly absorbing oral formulations of PDE 5 inhibitors
BRPI0616633A2 (pt) * 2005-09-29 2011-06-28 Bayer Healthcare Ag inibidores de pde e combinações dos mesmos para o tratamento de transtornos urológicos
EP2116264B1 (en) * 2006-12-26 2017-09-27 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
WO2008100933A2 (en) * 2007-02-12 2008-08-21 Dmi Biosciences, Inc. Reducing side effects of tramadol
KR20100029762A (ko) * 2007-06-13 2010-03-17 바이엘 쉐링 파마 악티엔게젤샤프트 청력 장애 치료용 pde 억제제
FR2932682B1 (fr) * 2008-06-23 2013-07-12 Bionetwork Nouvelles formes pharmaceutiques a effet rapide et les utilisations des compositions pharmaceutiques ainsi obtenus.
WO2010104563A2 (en) 2009-03-09 2010-09-16 Spi Pharma, Inc. Highly compactable and durable direct compression excipients and excipient systems
DE102009016584A1 (de) 2009-04-06 2010-10-07 Ratiopharm Gmbh Schmelztablette, enthaltend ein Sildenafil-Salz
WO2010131486A1 (en) * 2009-05-15 2010-11-18 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
WO2011013003A2 (en) * 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
WO2011030351A2 (en) 2009-09-03 2011-03-17 Rubicon Research Private Limited Taste - masked pharmaceutical compositions
EP2338474A1 (de) * 2009-12-23 2011-06-29 Ratiopharm GmbH Oral dispersible Tablette enthaltend kompaktierte Sildenafil-Base
DE102010024866A1 (de) * 2010-06-24 2011-12-29 Pharmatech Gmbh Formulierung zur Geschmacksmaskierung
MX349803B (es) * 2011-02-11 2017-08-14 Ctc Bio Inc Preparación farmacéutica de película que contiene sildenafil en su forma de base libre y método para producir dicha preparación.
KR101418406B1 (ko) * 2011-08-24 2014-07-10 한미약품 주식회사 실데나필 유리 염기를 포함하는 구강 붕해정
MX366768B (es) * 2011-12-08 2019-07-17 Laboratorios Liomont S A De C V Tableta orodispersable de sildenafil y metodo para preparar la misma.
KR102239291B1 (ko) 2013-06-28 2021-04-14 한미약품 주식회사 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
CN105769887B (zh) * 2014-12-23 2019-04-30 上海复星星泰医药科技有限公司 一种复方果糖二磷酸钠果糖口崩片及其制备方法
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
CN114246835A (zh) * 2022-01-05 2022-03-29 河北龙海药业有限公司 一种枸橼酸西地那非口腔崩解片的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2246013A1 (de) * 1972-09-20 1974-03-28 Boehringer Mannheim Gmbh Verfahren zur herstellung von poroesen tabletten
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
DE19532142A1 (de) * 1995-08-31 1997-03-06 Siemens Ag Verfahren und Vorrichtung zur Regelung eines vierdimensionalen Vektors einer Strecke mittels eines wertediskreten Stellgliedes mit begrenzter Schaltfrequenz
GB9523752D0 (en) * 1995-11-21 1996-01-24 Pfizer Ltd Pharmaceutical formulations
IL132993A0 (en) * 1997-05-29 2001-03-19 Mochida Pharm Co Ltd Therapeutic agent for erection failure
TW542719B (en) * 1998-02-23 2003-07-21 Pfizer Res & Dev Method of treating impotence due to spinal cord injury
US6124461A (en) * 1998-05-26 2000-09-26 Saint Louis University, Health Services Center, Research Administration Compounds, compositions, and methods for treating erectile dysfunction
WO2000054777A1 (en) * 1999-03-16 2000-09-21 Pentech Pharmaceuticals, Inc. Controlled release of sildenafil delivered by sublingual or buccal administration

Also Published As

Publication number Publication date
SK61599A3 (en) 2000-12-11
PE20000546A1 (es) 2000-07-07
SG79255A1 (en) 2001-03-20
EA199900373A2 (ru) 1999-12-29
TR199901077A2 (en) 1999-12-21
CO5060503A1 (es) 2001-07-30
AU2812699A (en) 1999-11-25
AU753478B2 (en) 2002-10-17
BR9902086A (pt) 2000-05-02
HU9901606D0 (en) 1999-07-28
HRP990144A2 (en) 2000-02-29
NZ335772A (en) 2000-12-22
NO992339L (no) 1999-11-16
CN1251758A (zh) 2000-05-03
GT199900061A (es) 2000-10-14
ZA993338B (en) 2000-11-14
EA199900373A3 (ru) 2000-08-28
AP9901534A0 (en) 1999-06-30
OA11040A (en) 2003-01-01
PL333118A1 (en) 1999-11-22
BG103396A (bg) 2000-01-31
CA2272042A1 (en) 1999-11-15
NO992339D0 (no) 1999-05-14
TR199901077A3 (tr) 1999-12-21
HN1999000066A (es) 1999-09-29
US20020002172A1 (en) 2002-01-03
HUP9901606A2 (en) 2002-09-28
EP0960621A2 (en) 1999-12-01
DZ2786A1 (fr) 2003-12-01
YU21999A (sh) 2002-03-18
AR016481A1 (es) 2001-07-04
MA26629A1 (fr) 2004-12-20
ID23299A (id) 2000-04-05
JPH11349483A (ja) 1999-12-21
IS5046A (is) 1999-11-16
EA002830B1 (ru) 2002-10-31
KR19990088249A (ko) 1999-12-27
EP0960621A3 (en) 2000-01-05

Similar Documents

Publication Publication Date Title
GT199900061A (es) Formulaciones farmaceuticas.
ID27504A (id) Formulasi oral baru
HN1998000115A (es) Formas de dosificación farmacéuticas sólidas
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
ES2539945T3 (es) Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas
HN2001000224A (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
ITMI20011337A0 (it) Composizioni farmaceutiche orali a rilascio modificato del principio attivo
HN1997000151A (es) Forma de dosificacion farmaceutica que enmascara el sabor y que se libera rapidamente.
AT7729U3 (de) Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat
NO20011217D0 (no) Doseringsform omfattende væskeformulering
ATE301999T1 (de) Racecadotril enthaltende trockene pulverformulierung
CR8003A (es) Composiciones limpiadoras en la forma de una tableta
HN2001000262A (es) Kit de repinotano
ES2170143T3 (es) Composiciones que comprenden halofantrina en una forma especial.
ITMI20011338A0 (it) Composizioni farmaceutiche orali a rilascio immediato del principio attivo
GT199800091A (es) Formas de dosificacion de sertralina de liberacion retardada.
HN2003000115A (es) Formulacion farmaceutica que comprende melatonina
ATE297760T1 (de) Pharmazeutische zusammensetzungen enthaltend terbinafin
HN2001000137A (es) Procedimiento para la fabricacion de una forma farmaceutica semi solida conteniendo dexketoprofeno trometamol y su utilizacion en el tratamiento topico de la inflamacion
GT199800090A (es) Formas de dosificacion de solucion encapsulada de sertralina.
GT200400183A (es) Formas de dosificacion de azitromicina con efectos secundarios reducidos
MX9400677A (es) Profarmacos de 3-acil-2-oxindol-1-carboxamidas antiinflamatorias.
PA8644501A1 (es) Composicion farmaceutica
PA8558501A1 (es) 1,3-diarilprop-2-en1-onas, composiciones que las contienen y su utilizacion
ES2182931T3 (es) Composiciones farmaceuticas para uso topico sobre la base de ketoprofeno.